Clinical trials
Chronic Liver Disease clinical trials
Below are recruiting chronic liver disease clinical trials, each written for real people, not researchers. We’re tracking 388 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07237750Recruiting
Weight loss trial: endoscopy procedure vs lifestyle changes
This study compares a new endoscopic procedure (a stomach tightening treatment done through a tube in your mouth) with a structured diet and exercise program to help with weight loss. It is for Asian adults who have tried and failed to lose weight before.
Beijing, Beijing MunicipalityAges 18–65 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT07198854Recruiting
Stem cell treatment for liver failure in hepatitis B patients
This trial looks at how well stem cell (MSC) treatment works for people with severe liver failure caused by hepatitis B. It checks what factors affect the success of the treatment.
Guangzhou, GuangdongAges 18 years+ - NCT07185932RecruitingEarly Phase 1
Rifaximin for fatty liver with metabolic issues
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07162350Recruiting
Food as medicine for kids with health risks
This study tests whether extra healthy food and nutrition help can improve health in children ages 8-15 who have a high body mass index (BMI). It is for children seen at certain Parkland clinics who have not seen a dietitian in the past year.
Dallas, TexasAges 8–15 - NCT07143968RecruitingPhase 2
Resmetirom for people with MASLD and HIV
This study tests if resmetirom can help people who have both HIV and a liver condition called MASLD (fat buildup in the liver not caused by alcohol). You may qualify if your liver has a certain amount of fat and stiffness, and your HIV is well controlled with stable medication.
Birmingham, AlabamaAges 18 years+ - NCT07120464Recruiting
Rabies vaccine study for people with weak immune systems or older age
This study tests how well a rabies vaccine works and how safe it is for people whose immune systems may be weaker, such as those with certain long-term illnesses, organ transplants, or age 60 and older. It compares them to healthy adults ages 18 to 59.
Shenzhen, GuangdongAges Any age - NCT06968234Recruiting
Liver disease breath test study
This study uses a special breath test to learn about chronic liver disease. If you have liver disease or cirrhosis, you may be able to help by providing a breath sample.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07046819RecruitingPhase 2
Tirzepatide for liver disease linked to alcohol use
This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.
Bethesda, MarylandAges 21–100 - NCT07022197RecruitingPhase 1/Phase 2
BAFF-R CAR T cells for severe nerve and immune diseases
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06895018Enrolling by invitation
Grape Drink Trial for Diabetes and Fatty Liver
This study tests a drink made from grape pomace (a natural byproduct) that is rich in polyphenols—compounds that may help the liver and heart. Participants have type 2 diabetes and mild fatty liver, and researchers want to see if the drink improves liver health, blood sugar, and gut bacteria over several months.
NaplesAges 35–70 - NCT06820970Recruiting
Combined therapy for heart artery blockages that weren't fully opened
This trial tests if combining a new heart procedure with a special type of therapy called mindfulness therapy can help prevent heart problems in people with coronary artery disease that could not be fully fixed with stents or surgery.
Zhengzhou, HenanAges 18 years+ - NCT04496479RecruitingPhase 2
Transplanting donor liver cells near lymph nodes in advanced liver disease
This Phase 2 study tests whether transplanting donor liver cells near lymph nodes can improve outcomes in people with advanced cirrhosis from certain liver conditions. It may help your liver function by adding healthy liver cells, but eligibility is tightly based on your current liver status and other health factors.
Boston, MassachusettsAges 18–70 - NCT06701825RecruitingPhase 4
Genetic testing before tacrolimus in kidney transplant
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
Madrid, MadridAges Any age - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT06571474Recruiting
Fat Cell Function in Obesity and Metabolism Study
This study looks at how a type of immune cell (macrophage) in fat tissue processes lipids, and how that affects metabolism in people with different body weights. It may help us understand why some people with obesity develop diabetes and fatty liver while others do not.
Columbia, MissouriAges 18–70 - NCT06562803Recruiting
Cleaning the blood for liver failure with sepsis
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
Guangzhou, GuangdongAges 18–70 - NCT06453915RecruitingEarly Phase 1
Brain PET scan for inflammation in fatty liver disease
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
Sacramento, CaliforniaAges 18 years+ - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT06274788Recruiting
Safety study of long-term Omegaven for liver problems from IV nutrition
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
Fountain Valley, CaliforniaAges 1 day–17 years - NCT05178069RecruitingPhase 2
Probiotic supplement study for alcohol use disorder and liver injury
This Phase 2 trial studies whether a probiotic (LGG) can improve health in people with alcohol use disorder and alcohol-related liver injury. It’s not an alcohol treatment study, so participants are mainly joining to see how the supplement affects the body and liver-related outcomes.
Louisville, KentuckyAges 21–65 - NCT05881005Recruiting
NAC for fatty liver in people with active Cushing’s
This study tests whether NAC (a supplement/medicine) can improve liver health in adults who have active Cushing’s syndrome and fatty liver disease. It may help if your excess stress hormone levels are affecting your liver.
AngersAges 18 years+
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease?
- Yes. Clin2 currently lists 388 recruiting chronic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.